Taehee Kim

ORCID: 0000-0003-2252-1387
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Urticaria and Related Conditions
  • Autoimmune Bullous Skin Diseases
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • RNA regulation and disease
  • Reconstructive Facial Surgery Techniques
  • Cutaneous lymphoproliferative disorders research
  • Skin Protection and Aging
  • Dermatologic Treatments and Research
  • Skin and Cellular Biology Research
  • Wnt/β-catenin signaling in development and cancer
  • Plasma Applications and Diagnostics
  • Nonmelanoma Skin Cancer Studies
  • Ear and Head Tumors

Gangnam Severance Hospital
2022-2024

Yonsei University
2022-2024

BACKGROUNDPemphigus, a rare autoimmune bullous disease mediated by antidesmoglein autoantibodies, can be controlled with systemic medication like rituximab and high-dose corticosteroids combined immunosuppressants. However, some patients continue to experience chronically recurrent blisters in specific area require long-term maintenance therapy.METHODSSkin chronic was obtained from pemphigus. Immunologic properties of the skin were analyzed immunofluorescence staining, bulk single-cell RNA...

10.1172/jci166357 article EN cc-by Journal of Clinical Investigation 2023-10-10

Reconstruction of lips after squamous cell carcinoma (SCC) removal should restore functional and aesthetic roles; however, it remains a challenge. In this study we describe the clinical features lip SCC suggest reconstruction algorithm. We retrospectively analyzed 34 patients with who underwent Mohs micrographic surgery between January 2006 March 2022. The mean age was 70.2 years. Seven tumors were on upper 27 lower lip. Twenty-five defects located mucosal lip, eight involved both cutaneous...

10.1111/1346-8138.17181 article EN The Journal of Dermatology 2024-03-05

Patients with refractory bullous pemphigoid (BP) achieve remission after rituximab treatment but require high-dose systemic corticosteroids until the remission. The aim of this retrospective study was to examine clinical efficacy omalizumab as an adjuvant in patients BP. BP receiving either monotherapy or plus were considered for study. total dose received 60 days administration rituximab, mortality and relapse rates, median time also investigated. Of 49 included study, 25 17 combination...

10.1111/1346-8138.16678 article EN The Journal of Dermatology 2022-12-13

Background . Although several energy devices targeting sebaceous glands have been developed, an effective and safe therapeutic tool for hyperseborrhea is still needed. Nonthermal atmospheric‐pressure plasma (NTAPP) induces microscopic tissue reactions in of rat skin. Objective The aim the study to investigate effects NTAPP on sebum production human skin vivo followed by experimental sebocytes. Methods Fourteen healthy volunteers with oily facial underwent three sessions argon‐ nitrogen‐NTAPP...

10.1155/2023/2922191 article EN cc-by Dermatologic Therapy 2023-01-01

Epidermolytic ichthyosis (EI) is a rare genetic disorder of keratinization caused by mutations in either KRT1 or KRT10. Histopathologically, epidermolytic hyperkeratosis (EHK) hallmark EI. Here, we report two EI cases which mutation was confirmed molecular study, but without typical EHK present on skin biopsies performed within 1 week age. Our demonstrate that may not be evident if biopsy during the neonatal period.

10.1111/pde.15354 article EN Pediatric Dermatology 2023-05-11
Coming Soon ...